No Data
Chongqing Zhifei Biological Products (300122.SZ): Application for clinical trial of DTP-Hib quadrivalent vaccine has been accepted.
On February 21, Gelonghui reported that Chongqing Zhifei Biological Products (300122.SZ) announced that its wholly-owned subsidiary, Peking Zhifei Lvzhun Biological Pharmaceutical Co., Ltd., has developed an adsorbed acellular DTP (component) type B Haemophilus influenzae (combined) vaccine (referred to as the "Component DTP-Hib Quadrivalent Vaccine"), which has received the Clinical Trial Application Acceptance Notification from the National Medical Products Administration (Acceptance No: CXSL2500171). Within 60 days from the date of acceptance, if no negative or questionable comments are received from the drug review center, Zhifei Lvzhun can commence clinical trials according to the submitted plan. Pertussis is caused by the Bordetella pertussis bacteria.
We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt
Express News | Zhifei Biological Products Sees 2024 Net Profit 67-77% Y/Y
Zhifei Biotech: 2025-02 2024 Annual Performance Forecast
Chongqing Zhifei Biological Products (300122.SZ): Application for clinical trial of adjuvanted trivalent influenza vaccine has been accepted.
Chongqing Zhifei Biological Products (300122.SZ) announced that its wholly-owned subsidiary Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd. (...)
Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
102884128 : getting disappointed with this counter. every day drop.